Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00069 / http://dx.doi.org/10.20960/revcancer.00069

Resumen| PDF

Revisión

Carcinoma de cabeza y cuello en pacientes no candidatos a platino

Zara Vidales Sepúlveda, Marc Oliva Bernal

Prepublicado: 2024-03-21

Logo Descargas Número de descargas: 782 Logo Visitas Número de visitas: 124 Citas Citas: 0

Compártelo:

El cisplatino es un componente esencial del tratamiento del carcinoma escamoso de cabeza y cuello, tanto en la enfermedad localmente avanzada como en la recurrente/metastásica. Sin embargo, la toxicidad aguda y crónica del cisplatino no es asumible en todos los pacientes; está contraindicado absoluta o relativamente en diferentes situaciones clínicas. A lo largo de este trabajo se resume la evidencia disponible de combinaciones libres de cisplatino para el tratamiento de la enfermedad localizada como la recurrente/metastásica.

Palabras Clave: Inelegible cisplatino. Frágil. Tratamiento adaptado.

Descargar PDF

Bibliografía
Artículos Relacionados

Ahn MJ, D’Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQT, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncol 2016;53:10-6.
DOI: 10.1016/j.oraloncology.2015.11.019

Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet (London, England) 2013;381(9868):752-62.
DOI: 10.1016/S0140-6736(12)62167-9

Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004;22(2):262-8.
DOI: 10.1200/JCO.2004.08.039

Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281-93.
DOI: 10.1016/j.radonc.2021.01.013

Ward MC, Reddy CA, Adelstein DJ, Koyfman SA. Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. Cancer 2016;122(22):3472-83.
DOI: 10.1002/cncr.30214

Mayer A, Wenzel W, Wollschläger D, Bostel T, Krüger M, Matthias C, et al. Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlentherapie und Onkol 2022;198(2):159-70.
DOI: 10.1007/s00066-021-01890-2

Smile TD, Reddy CA, Matia B, Fleming CW, Domb C, Geiger JL, et al. A Reappraisal of Definitive Chemoradiotherapy for Older Adults with Advanced Head and Neck Cancer. Anticancer Res 2022;42(8):3845-52.
DOI: 10.21873/anticanres.15875

Falco A, de Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galindo H, et al. Ibero-american expert consensus on squamous cell carcinoma of the head and neck treatment in patients unable to receive cisplatin: Recommendations for clinical practice. Cancer Manag Res 2021;13:6689-703.
DOI: 10.2147/CMAR.S322411

Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: Secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol 2015;10(1):1-7.
DOI: 10.1186/s13014-014-0319-y

De Castro G, Alves GV, Castro AF, Chaves ALF, De Marchi P, de Oliveira TB, et al. Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. Crit Rev Oncol Hematol 2018;131:30-4.
DOI: 10.1016/j.critrevonc.2018.08.009

Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc 2016;91(3):386-96.
DOI: 10.1016/j.mayocp.2015.12.017

Bakas AT, Polinder-Bos HA, Streng F, Mattace-Raso FUS, Ziere G, de Jong RJB, et al. Frailty in Non-geriatric Patients with Head and Neck cancer. Otolaryngol - Head Neck Surg (United States) 2023;169(5):1215-24.
DOI: 10.1002/ohn.388

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: A systematic review. Ann Oncol 2015;26(6):1091-101.
DOI: 10.1093/annonc/mdu540

Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 2014;32(24):2595-603.
DOI: 10.1200/JCO.2013.54.8347

Goede V. Frailty and Cancer: Current Perspectives on Assessment and Monitoring. Clin Interv Aging 2023;18:505-12.
DOI: 10.2147/CIA.S365494

Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol Off J Eur Soc Med Oncol 2015;26(2):288-300.
DOI: 10.1093/annonc/mdu210

Swartz LK, Swiecicki PL. Head and Neck Cancers. Oncol Board Rev Bluepr Study Guid. Q&A Third Ed; 2021. p. 185-95.

Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75.
DOI: 10.1016/j.annonc.2020.07.011

Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol 2021;23(5):913-21.
DOI: 10.1007/s12094-020-02533-1

Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22(1):69-76.
DOI: 10.1200/JCO.2004.08.021

Li Q, Guan J, Zhang Y, Chen M, Li L, Xiao N, et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). J Clin Oncol 2015;33(Suppl.15):6036-6036.
DOI: 10.1200/jco.2015.33.15_suppl.6036

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8.
DOI: 10.1016/S1470-2045(09)70311-0

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51-60.
DOI: 10.1016/S0140-6736(18)32752-1

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (London, England) 2019;393(10166):40-50.
DOI: 10.1016/S0140-6736(18)32779-X

Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, et al. Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. J Clin Oncol Off J Am Soc Clin Oncol 2023;41(13):2350-61.
DOI: 10.1200/JCO.22.00980

Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017;18(9):1221-37.
DOI: 10.1016/S1470-2045(17)30458-8

Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, et al. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol 2018;84:46-51.
DOI: 10.1016/j.oraloncology.2018.06.028

Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, et al. Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. Clin Transl Oncol 2021;23(8):1666-77.
DOI: 10.1007/s12094-021-02567-z

Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma a randomized clinical trial. JAMA Oncol 2017;3(2):220-6.
DOI: 10.1001/jamaoncol.2016.4510

Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Arya S, et al. Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patient’s ineligible for 3 weekly maximum tolerable dose chemotherapy. Indian J Cancer 2014;51(1):20-4.
DOI: 10.4103/0019-509X.134608

Shirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, et al. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patient’s ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. Int J Clin Oncol 2020;25(11):1914-20.
DOI: 10.1007/s10147-020-01742-6

Marín-Jiménez JA, Oliva M, Peinado Martín P, Cabezas-Camarero S, Plana Serrahima M, Vázquez Masedo G, et al. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy. Front Oncol 2022;12:1-10.
DOI: 10.3389/fonc.2022.953020

Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 2014;32(23):2486-95.
DOI: 10.1200/JCO.2013.53.9163

Ngamphaiboon N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C. Oral Oncology 2023;145.
DOI: 10.1016/j.oraloncology.2023.106520

Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 2023;34(1):101-10.
DOI: 10.1016/j.annonc.2022.10.006

Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann Oncol 2021;32(I):S1310.
DOI: 10.1016/j.annonc.2021.08.2112

Thomson DJ, Slevin NJ, Baines H, Betts G, Bolton S, Evans M, et al. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy with Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD). Int J Radiat Oncol Biol Phys 2023;S0360-3016(23)08184-1.

Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, et al. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin cancer Res an Off J Am Assoc Cancer Res 2018;24(20):4949-59.
DOI: 10.1158/1078-0432.CCR-18-0467

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008;359(11):1116-27.
DOI: 10.1056/NEJMoa0802656

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856-67.
DOI: 10.1056/NEJMoa1602252

Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab Alone or with Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022;40(21):2321-32.
DOI: 10.1200/JCO.21.02198

Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phas. Lancet Oncol 2021;22(4):463-75.
DOI: 10.1016/S1470-2045(20)30755-5

Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, et al. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol 2021;26(3):494-506.
DOI: 10.1007/s10147-020-01829-0

Thapa DA, Cowell DA, Peters DA, Noble DDJ, James DA, Lamb DC, et al. The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland. Clin Oncol (R Coll Radiol) 2024:S0936-6555(24)00071-2.
DOI: 10.1016/j.clon.2024.02.004

Wu Q, Wang Q, Tang X, Xu R, Zhang L, Chen X, et al. Correlation between patients’ age and cancer immunotherapy efficacy. Oncoimmunology 2019;8(4):1-9.

Gomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study. ESMO Open 2021;6(1):100042.
DOI: 10.1016/j.esmoop.2020.100042

Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012;23(4):1016-22.
DOI: 10.1093/annonc/mdr367

Rubió-Casadevall J, Cirauqui Cirauqui B, Martínez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, et al. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2023;13:1-14.
DOI: 10.3389/fonc.2023.1226939

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28.
DOI: 10.1016/S0140-6736(19)32591-7

Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2023;41(4):790-802.
DOI: 10.1200/JCO.21.02508

Dzienis MR, Cundom JE, Fuentes CS, Hansen AR, Nordlinger MJ, Pastor AV, et al. 651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol 2022;33:S839-40.
DOI: 10.1016/j.annonc.2022.07.775

Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 2023;41(12):2166-80.
DOI: 10.1200/JCO.22.00332

Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol 2023;34(3):262-74.
DOI: 10.1016/j.annonc.2022.12.008

Fayette J, Licitra LFL, Harrington KJ, Haddad R, Siu LL, Liu YC, et al. 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI). Ann Oncol 2023;34:S554-5.
DOI: 10.1016/j.annonc.2023.09.2000

Kong AH, Klein Hesselink MS, Aguilera B, Adkins D, Even C, Fayette J, et al. Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy. J Clin Oncol 2023;41(Suppl.16):6028-6028.
DOI: 10.1200/JCO.2023.41.16_suppl.6028

Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021;22(6):883-92.
DOI: 10.1016/S1470-2045(21)00136-4

Bauman J, Cancer GW. 2024 Multidisciplinary Head and Neck Cancers 2024 Multidisciplinary Head and Neck Cancers Symposium; 2024.

Melero I, Castanon E, Álvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 2021;18(9):558-76.
DOI: 10.1038/s41571-021-00507-y

Fayette J, Cropet C, Gautier J, Toullec C, Burgy M, Bruyas A, et al. Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. J Clin Oncol 2023;41(Suppl.16):6003-6003.
DOI: 10.1200/JCO.2023.41.16_suppl.6003